Short answer
Lucid Diagnostics Inc. (LUCD) filed an 8-K current report with the SEC on August 13, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Item 2.02 references furnished information under Items 2.02 and 7.01.
Lucid Diagnostics Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Item 2.02 references furnished information under Items 2.02 and 7.01
- No operating results or financial figures included in the provided text
- Exhibit contains the substantive disclosure, but is not provided here
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $1.474 million, up from $1.163 million, with 2,770 EsoGuard tests processed
- Concert secured first laboratory benefit manager coverage policy, with multiple client health plans adopting it
- GAAP net loss attributable to common stockholders $14.715 million, including $3.028 million preferred-stock dividends
- Cash $33.4 million at June 30, 2026, versus $34.7 million at December 31, 2025
- Non-GAAP adjusted loss $10.854 million, or $0.06 per share, highlighting continued funding needs despite commercial progress
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Lucid Diagnostics Inc. 8-K filings
Get the next LUCD 8-K as it lands
Follow LUCD for push alerts, or ask the research agent what this filing means.